help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jaffe, C. A.
Right arrow Articles by Barkan, A. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jaffe, C. A.
Right arrow Articles by Barkan, A. L.
The Journal of Clinical Endocrinology & Metabolism Vol. 86, No. 9 4364-4370
Copyright © 2001 by The Endocrine Society


Other Original Articles

Regulation of GH Secretion in Acromegaly: Reproducibility of Daily GH Profiles and Attenuated Negative Feedback by IGF-I

Craig A. Jaffe, Wenqin Pan, Morton B. Brown, Roberta DeMott-Friberg and Ariel L. Barkan

Division of Endocrinology and Metabolism, Department of Internal Medicine, Department of Veterans Affairs Medical Center, and University of Michigan Medical Center and Department of Biostatistics, School of Public Health (W.P., M.B.B.), University of Michigan, Ann Arbor, Michigan 48109

Address all correspondence and requests for reprints to: Craig A. Jaffe, M.D., Division of Endocrinology and Metabolism, University of Michigan Medical Center, 3920 Taubman Center, 1500 Medical Center Drive, Ann Arbor, Michigan 48109-0354. E-mail: cjaffe{at}umich.edu

Abstract

GH hypersecretion is a hallmark of acromegaly. It is unknown whether the secretory activity of somatotroph adenoma is autonomous or is still governed by central or peripheral mechanisms. In this study we investigated whether GH secretion in acromegaly 1) has a reproducible circadian pattern and 2) is inhibited by exogenous IGF-I. Eleven patients with newly diagnosed acromegaly were studied in 2 protocols. In protocol 1, peripheral blood was sampled every 10 min for 48 h in 6 patients for the determination of concordance between 24-h GH profiles. There was no significant day to day variability in mean 24-h output. There was, however, a significant time effect, and the 24-h GH secretion pattern was maintained between days. In protocol 2, 5 patients were sampled for GH every 10 min twice, once during infusion of normal saline and once during iv infusion of recombinant human IGF-I (10 µg/kg·h). The recombinant human IGF-I infusion increased plasma IGF-I to approximately 230% of the baseline concentration. This resulted in GH suppression (4220 ± 1950 vs. 3223 ± 1472 µg/liter·min; P = 0.001), but did not alter GH secretion pattern. There were highly significant cross-correlations for 10 of the 11 of the subjects in the two protocols when the lag was 0 min. By harmonic analysis, nocturnal augmentation of GH was maintained, and maximum daily GH occurred at approximately 2300 h. These data demonstrate that the pattern of GH secretion in acromegaly is not random, but is highly preserved with 24-h periodicity. In addition, negative feedback regulation by IGF-I is preserved, although the degree of negative feedback is grossly attenuated. Thus, secretory activity of somatotroph adenomas is not autonomous or haphazard, but is still subject to both feedback and feedforward regulatory mechanisms.




This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
M. Mercado, B. Gonzalez, C. Sandoval, Y. Esquenazi, F. Mier, G. Vargas, A. L. E. de los Monteros, and E. Sosa
Clinical and Biochemical Impact of the d3 Growth Hormone Receptor Genotype in Acromegaly
J. Clin. Endocrinol. Metab., September 1, 2008; 93(9): 3411 - 3415.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
C. Schmid, P.-A. Krayenbuehl, R.-L. Bernays, C. Zwimpfer, F. E. Maly, and P. Wiesli
Growth Hormone (GH) Receptor Isoform in Acromegaly: Lower Concentrations of GH but Not Insulin-Like Growth Factor-1 in Patients with a Genomic Deletion of Exon 3 in the GH Receptor Gene
Clin. Chem., August 1, 2007; 53(8): 1484 - 1488.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
E. V. Dimaraki, W. F. Chandler, M. B. Brown, C. A. Jaffe, S. Y. Kim, R. Taussig, V. Padmanabhan, and A. L. Barkan
The Role of Endogenous Growth Hormone-Releasing Hormone in Acromegaly
J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2185 - 2190.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
L. Huo, G. Fu, X. Wang, W. K. W. Ko, and A. O. L. Wong
Modulation of Calmodulin Gene Expression as a Novel Mechanism for Growth Hormone Feedback Control by Insulin-like Growth Factor in Grass Carp Pituitary Cells
Endocrinology, September 1, 2005; 146(9): 3821 - 3835.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
N. R. Biermasz, A. M. Pereira, M. Frolich, J. A. Romijn, J. D. Veldhuis, and F. Roelfsema
Octreotide represses secretory-burst mass and nonpulsatile secretion but does not restore event frequency or orderly GH secretion in acromegaly
Am J Physiol Endocrinol Metab, January 1, 2004; 286(1): E25 - E30.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2001 by The Endocrine Society